![Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial - The Lancet Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial - The Lancet](https://www.thelancet.com/cms/attachment/2000996102/2003691747/gr1.gif)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial - The Lancet
![Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial - The Lancet Haematology Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/e2515398-d33a-4645-a140-68fdc983ada6/gr1_lrg.gif)
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial - The Lancet Haematology
![Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fnrgastro.2011.21/MediaObjects/41575_2011_Article_BFnrgastro201121_Fig1_HTML.jpg)
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology
![Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial - The Lancet Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2119418385/2093586859/gr1.gif)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial - The Lancet
![An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists | BMC Neurology | Full Text An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists | BMC Neurology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12883-019-1354-y/MediaObjects/12883_2019_1354_Fig1_HTML.png)
An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists | BMC Neurology | Full Text
![Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides - JDDonline - Journal of Drugs in Dermatology Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides - JDDonline - Journal of Drugs in Dermatology](https://s3.amazonaws.com/dl.jddonline.com/articleimages/20_3_WALKER/Clinical_Trial_of_High_Dose_Pegylated_Interferon_Alfa_2b_Combined_With_Phototherapy_in_Advanced_Stage_Mycosis_Fungoides_Table2.jpg)